ALK and non-small cell lung carcinoma: The chemotherapeutic activity of pemetrexed and durable responses to ALK‐TKIs, such as crizotinib, ceritinib, alectinib, and lorlatinib, can produce an median survival time (MST) of around 5 years in advanced ALK‐positive NSCLC 3, almost equivalent to the survival rate after surgical treatment of stage II NSCLC patients.